Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand
- PMID: 23777722
- PMCID: PMC4776827
- DOI: 10.5539/gjhs.v5n4p60
Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand
Abstract
Background: Isoniazid Preventive Therapy (IPT) has been recommended by WHO/UNAIDS for people living with HIV (PLWH) since 1993; however the uptake of IPT implementation has been very low globally. This study aims to assess the barriers to and motivations for the implementation of IPT for PLWH in upper northern Thailand, an area with a high tuberculosis (TB) and human immunodeficiency virus (HIV) burden.
Methods: A survey was carried out via self-administered questionnaires mailed to healthcare workers (HCW) in all 95 public hospitals in the upper northern region of Thailand. A reminding phone call, one month after sending the mail, was made.
Results: The response rate from the hospitals was 94% and from the HCW's, 70%. IPT programme was being implemented at only 18 (20%) out of the 89 public hospitals. The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%). The 38 HCWs from hospitals implementing IPT programme, were motivated by (1) knowledge that IPT can prevent TB (63%), (2) the following of national guideline (34%), (3) concern for TB prevention even after the expansion of access to antiretroviral therapy (ART) (32%).
Conclusion and recommendation: To implement an IPT programme for PLWH, giving a clear national policy and straightforward direction are necessary. Furthermore, provision of public health information and updated evidences may enhance HCW's comprehension of benefits and risks of IPT, thus it may increase the IPT programme implementation.
Figures
Similar articles
-
Implementing an isoniazid preventive therapy program for people living with HIV in Thailand.PLoS One. 2017 Sep 26;12(9):e0184986. doi: 10.1371/journal.pone.0184986. eCollection 2017. PLoS One. 2017. PMID: 28949995 Free PMC article.
-
A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.AIDS Res Ther. 2020 May 27;17(1):28. doi: 10.1186/s12981-020-00285-0. AIDS Res Ther. 2020. PMID: 32460788 Free PMC article.
-
Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.BMC Infect Dis. 2020 Apr 21;20(1):294. doi: 10.1186/s12879-020-05011-9. BMC Infect Dis. 2020. PMID: 32664847 Free PMC article.
-
Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries.Int J Tuberc Lung Dis. 2014 Oct;18(10):1149-58. doi: 10.5588/ijtld.13.0889. Int J Tuberc Lung Dis. 2014. PMID: 25216827 Review.
-
Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3(Suppl 3):S297-305. doi: 10.1097/QAI.0000000000000497. J Acquir Immune Defic Syndr. 2015. PMID: 25768869 Free PMC article. Review.
Cited by
-
How can we improve latent tuberculosis infection management using behaviour change wheel: a systematic review.J Public Health (Oxf). 2023 Aug 28;45(3):e447-e466. doi: 10.1093/pubmed/fdad051. J Public Health (Oxf). 2023. PMID: 37147919 Free PMC article.
-
Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa.Glob Public Health. 2022 Apr;17(4):555-568. doi: 10.1080/17441692.2021.1892793. Epub 2021 Mar 2. Glob Public Health. 2022. PMID: 33650939 Free PMC article.
-
Implementing an isoniazid preventive therapy program for people living with HIV in Thailand.PLoS One. 2017 Sep 26;12(9):e0184986. doi: 10.1371/journal.pone.0184986. eCollection 2017. PLoS One. 2017. PMID: 28949995 Free PMC article.
-
Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study.BMC Public Health. 2016 Aug 19;16(1):840. doi: 10.1186/s12889-016-3525-8. BMC Public Health. 2016. PMID: 27543096 Free PMC article.
-
Improving coverage and completion rate of isoniazid preventive therapy among eligible HIV patients using quality improvement approaches: a case study of State Hospital, Ijebu Ode, Ogun State, Nigeria.Pan Afr Med J. 2019 Dec 11;34:193. doi: 10.11604/pamj.2019.34.193.19360. eCollection 2019. Pan Afr Med J. 2019. PMID: 32180867 Free PMC article.
References
-
- Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;20(1) http://dx.doi.org/10.1002/14651858.CD000171.pub3 . - PMC - PubMed
-
- Ansari N. A., Kombe A. H., Kenyon T. A., Hone N. M., Tappero J. W., Nyirenda S. T., Lucas S. B. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int JTuberc Lung Dis. 2002;6(1):55–63. http://dx.doi.org/10.1016/j.tube.2007.05.003 . - PubMed
-
- Aung M. N., Moolphate S, Paudel D, Jayathunge P. H. M, Duangrithi D, Wangdi K, Higuchi K. Global evidence directing regional preventive strategies in Southeast Asia for fighting TB/HIV. The Journal of Infection in Developing Countries. 2013;7(03):191–202. http://dx.doi.org/10.3855/jidc.2903 . - PubMed
-
- Au-Yeung C, Kanters S, Ding E, Glaziou P, Anema A, Cooper C. L., Mills E. J. Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol. 2011;3:21–29. http://dx.doi.org/10.2147/CLEP.S15574 . - PMC - PubMed
-
- Balcells M. E., Thomas S. L., Godfrey-Faussett P, Grant A. D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744–751. http://dx.doi.org/10.3201/eid1205.050681 . - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous